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Hybrid positron emission tomography–magnetic resonance (PET-MR) imaging is a novel imaging modality with emerging applications for
cardiovascular disease. PET-MR aims to combine the high-spatial resolution morphological and functional assessment afforded by magnetic
resonance imaging (MRI) with the ability of positron emission tomography (PET) for quantification of metabolism, perfusion, and inflamma-
tion. The fusion of these two modalities into a single imaging platform not only represents an opportunity to acquire complementary in-
formation from a single scan, but also allows motion correction for PET with reduction in ionising radiation. This article presents a brief
overview of PET-MR technology followed by a review of the published literature on the clinical cardio-vascular applications of PET and
MRI performed separately and with hybrid PET-MR.
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Introduction
Positron emission tomography (PET) and magnetic resonance imag-
ing (MRI) are well established modalities for the investigation of car-
diovascular disease. MRI provides high-resolution information on
anatomy, morphology, function, and tissue characteristics. Parametric
mapping with MRI allows visualization of quantitative changes in the
myocardium based on changes in T1, T2, T2* and allows detection of
myocardial fibrosis, infiltration, and inflammation and iron overload.1
PET allows assessment of physiological processes by labelling bio-
logical compounds with positron emitting radionuclides2 and is the
reference standard for non-invasive assessment of myocardial perfu-
sion and absolute myocardial blood flow (MBF), myocardial metabol-
ism, and inflammation. Integrated PET and MRI may confer synergistic
value from image co-registration, motion correction, and reduction
in ionising radiation for clinical applications.
This article presents a brief overview of positron emission
tomography–magnetic resonance (PET-MR) technology followed by
a review of the published literature on the clinical cardio-vascular
applications of PET and MRI performed separately and with hybrid
PET-MR.
Technical considerations
Simultaneous PET-MR was first demonstrated in preclinical phantom
models in 1997.2 Presently, two configurations of PET-MR systems
exist for clinical studies. The Philips Ingenuity PET-MR (Philips
Medical Systems, the Netherlands) allows sequential imaging with a
turntable aligned to the PET and MRI gantry. The Siemens Biograph
mMR PET-MR (Siemens Healthcare, Germany) and GE Signa PET-
MR (GE Healthcare, Waukesha) are fully integrated systems in the
same gantry for true simultaneous PET and MRI acquisition.
The integration of PET and MRI systems in a single hardware plat-
form presented several technical challenges.2 A major obstacle was
the production of MRI compatible PET detectors that could operate
safely and efficiently within an MRI scanner. In addition, rapidly alter-
nating gradient fields of an MRI scanner could induce eddy currents in
PET circuitry and lead to signal loss, heating, and vibration.2
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MRI radiofrequency pulses cause electronic interference with stand-
ard PET detectors. On the other hand, standard ferromagnetic PET
detectors may cause inhomogeneities in the magnetic field and lead
to susceptibility artefacts and degrade MRI quality. Innovative solu-
tions overcame these challenges, particularly the development of
PET detectors that operate within a strong magnetic field.2
Attenuation correction
Quantitative PET data requires an accurate method for photon at-
tenuation, which occurs when photons that undergo annihilation are
absorbed by the body. As such, PET pixel values need to be scaled to
radioactivity concentrations units.3 In PET-CT, attenuation correc-
tion (AC) of PET data is derived from computed tomography (CT)
data, which are rescaled from Hounsfield units to 511-keV linear at-
tenuation coefficients to generate robust l-maps.4 In PET-MR, AC is
challenging as MRI signal intensity reflects proton density, which has
no direct relationship with tissue density or photon absorption as do
CT data.5 In PET-MR, attenuation maps are commonly derived from
Dixon MRI sequences,6 which are then used to segment discrete ana-
tomical regions into air, lung, fat, or soft tissue with known linear at-
tenuation coefficients,7 and voxels that belong to these tissue classes
are assigned a corresponding linear attenuation coefficient.8
Published comparisons between PET-CT and PET-MR quantitative
data have demonstrated comparable standardized uptake values
(SUV) of cardiac 18F-fluorodeoxyglucose (18F-FDG).9–12 Respiratory
misalignment commonly occurs with MRI-based AC maps, and me-
tallic artefact produces voids, but these can be corrected with manual
adjustment and importantly were found not to impact quantitative
PET data.13
However, there are several challenges to AC with PET-MR, in par-
ticular, cortical bone (the tissue that contributes the greatest to at-
tenuation) and air have low MRI signal, yet both are at the extremes
of photon attenuation. Standard Dixon based MRI-based AC maps
do not consider bone and solutions have been proposed with a
Dixon based model-based bone segmentation algorithm14 and ultra-
short echo time (UTE) sequences.8,15
Motion correction
Hybrid PET-MR has potential to provide high-resolution MRI data
with excellent soft-tissue contrast to track respiratory movement to
motion-correct PET data.16 Multiple radiation-free MRI acquisitions
can be acquired simultaneously to enhance image quality and quanti-
tative PET data. Several studies have demonstrated significant respira-
tory motion correction and improvement in accuracy of quantitative
SUV with MRI respiratory motion data.17–19 Furthermore, methods
are developing for highly efficient MRI motion correction models to
simultaneously correct coronary MRI and PET data with potential to
enhance PET-MR imaging.20
Clinical applications of PET-MR
There are many potential clinical applications for PET-MR in cardio-
vascular imaging, but to date, the development has focussed on a
small number of applications, which are discussed below.
Myocardial perfusion imaging
MRI and PET perfusion imaging are both in routine clinical use for is-
chaemia testing with similar levels of evidence in European Society of
Cardiology guidelines for diagnosis of stable angina.21
MRI
Myocardial perfusion MRI tracks the first myocardial passage of a
gadolinium-based contrast agent (GBCA) following intravenous in-
jection. GBCAs shorten T1-relaxation time and increase signal inten-
sity on T1-weighted MRI pulse sequences, which are used to acquire
a dynamic series of images. Typically combined with vasodilator
stress, myocardial perfusion MRI for ischaemia assessment is recom-
mended in patients with intermediate risk of coronary artery disease
(CAD).21
In meta-analyses, myocardial perfusion MRI has a sensitivity of 87%
and 89% and specificity of 91% and 87% at the vessel-level and
patient-level respectively when compared with invasive fractional
flow reserve as the reference standard.22 Absolute MBF quantifica-
tion with MRI is feasible and provides independent incremental prog-
nostic value compared with visual analysis.23 Techniques for fully
automated, free-breathing, pixel-wise MBF quantification with MRI
showed good agreement against PET, and promise to accelerate
adoption into clinical practice.24,25
PET
Perfusion PET tracers (Table 1) are generated by cyclotron (15O-
Water, 13N-Ammonia, 18F-Flurpiridaz) or generator (Rubidium-82)
and allow visual or fully quantitative assessment of myocardial perfu-
sion at rest and stress. A meta-analysis demonstrated sensitivity 92%
and specificity 85% for PET to detect angiographically defined
CAD.29 A normal PET perfusion scan is associated with a <1% annual
cardiac event rate, while an abnormal scan indicates adverse
prognosis.30,31
PET is the in vivo reference standard for MBF quantification.32 PET
MBF is superior to visual analysis for CAD detection and improves
diagnostic accuracy in multi-vessel CAD and microvascular dis-
ease.33–35 A reduced myocardial perfusion reserve (MPR), ratio of
stress: rest MBF, is an independent marker for adverse cardiovascular
outcome.36,37
PET-MR
There is only one published study on the use of hybrid PET-MR for
myocardial perfusion imaging. Twenty-nine patients underwent sim-
ultaneous stress and rest PET-MR perfusion with 13N-Ammonia and
first-pass GBCA MRI.38 A good correlation and agreement was
reported with MRI MBF compared with PET MBF, with improved
correlation after haematocrit correction to convert MRI plasma flow
values to blood flow. However, in keeping with previous studies
comparing MRI and PET MBF, MRI tended to overestimate MBF.
Potential reasons for this overestimation include the differences in
quantification algorithms between the methods and the fact that the
gold standard PET tracer 15O-Water was not used.
Future outlook
Although hybrid PET-MR perfusion imaging is an unlikely future clinic-
al application as both modalities measure MBF, PET-MR is an ideal
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dynamic conditions and remove physiological variation in measure-
ment. Emerging MRI methods for MBF quantification may be
compared against the gold standard PET tracer 15O-Water with po-
tential to provide an alternative future method for MBF quantification
that is free of ionizing radiation.
Viability
Viability assessment is most commonly used to predict functional re-
covery following revascularization. Both MRI and PET are in clinical
use, but take conceptually different approaches to viability/scar
assessment.
....................................................................................................................................................................................................................
Table 1 Physical properties of perfusion PET tracers
Radiotracer Half-life Availability Mechanism Comments
15O-Water 122 s On-site cyclotron Metabolically inert,
diffuses freely across
capillary membrane
Ideal tracer for MBF quantification, near perfect linear relationship
between flow and tracer uptake.26,27
100% myocardial extraction fraction.
Intermediate image quality due to long positron range.
13N-Ammonia 9.96 min On-site cyclotron Diffusion and metabolic
trapping
>80% myocardial extraction fraction.
High image quality due to short positron range and myocardial
retention.
Validated against 15O-Water.27,28
Rubidium-82 76 s Generator Myocardial uptake via Na/
K-ATPase
Short half-life allows rapid protocols.
MBF underestimation at high-flow rates due to roll-off phenomenon.
65% myocardial extraction fraction.
Moderate image quality due to long positron range.
18F-Flurpiridaz 110 min Regional cyclotron Rapid uptake by myocyte
mitochondrial complex
Near linear kinetics of tracer uptake and MBF.
Good image quality due to short positron range. High myocardial
extraction fraction (94%).
Current evaluation in Phase III trials. Does not require on-site cyclo-
tron and therefore allows greater access.
....................................................................................................................................................................................................................
Table 2 Radiotracers with potential clinical utility with PET-MR
Radiotracer Mechanism Potential use Future applications
18F-FDG Glucose analogue, undergoes
intracellular phosphoryl-
ation and trapped without
further metabolism
Viability
Inflammation
Sarcoidosis
Integrated 18F-FDG with dobutamine stress MRI, LGE, and mapping may
accurately predict functional recovery.
Potential for improved diagnostic accuracy and risk stratification in cardiac
sarcoidosis and myocarditis with combined mapping, LGE and 18F-FDG.
18F-Flouride Microcalcification Coronary plaque
imaging
Amyloid
Fused coronary anatomy with high-risk atherosclerotic inflammatory activ-
ity with 18F-Fluoride may predict plaque rupture to guide preventative
therapy.
May discriminate ATTR amyloid from AL amyloid.
68Ga-DOTATATE Binds to activated
inflammatory macrophages
Coronary plaque
imaging
Superior coronary imaging and better discriminator between culprit and
non-culprit lesions compared with 18F-FDG. Combined anatomical and
metabolic activity could be used to identify high-risk lesions prior to
rupture.
18F-Florbetaben Binds to b amyloid Amyloid Integrated T1-mapping and LGE with MRI with novel PET tracers may ac-
curately diagnose cardiac amyloid.
11C-Acetate Oxidative metabolism Viability assessment
Metabolic efficiency
assessment
Combined 11C-Acetate and low-dose-dobutamine may accurately predict
functional recovery following coronary revascularization or response to
cardiac resynchronization therapy.
964 M.S. Nazir et al.
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MRI
In clinical practice, MRI assessment of myocardial viability is most
commonly based on late gadolinium enhancement (LGE). The distri-
bution volume of the clinically used extracellular GBCAs is increased
in infarcted tissue due to its larger extracellular volume (ECV) and
slower clearance of GBCA. LGE imaging exploits these differences in
contrast concentration and generates images of myocardial scar with
high-tissue contrast and high-spatial resolution. On LGE, segments
with <25% transmural extent of infarction have a high likelihood of
functional recovery whereas segments with >75% transmural infarc-
tion are unlikely to recover after revascularization.39 An alternative
method for viability assessment with MRI is low-dose dobutamine
cine imaging, which has comparable accuracy to stress echocardiog-
raphy to detect functional reserve as a marker of viability. In a meta-
analysis, 50% subendocardial LGE had sensitivity (95%) and sensitivity
(51%) for prediction of functional recovery following
revascularization.40 Low-dose dobutamine had a lower sensitivity
(81%) but greater specificity (91%) to predict functional recovery.40
PET
Viability assessment by PET is based on metabolic assessment. 18F-
FDG is a radiolabelled glucose analogue that becomes trapped within
cardiac myocytes following intracellular uptake and provides strong sig-
nal for PET imaging.41,42 Optimal assessment of viability requires inte-
gration of perfusion and 18F-FDG uptake.42 Dysfunctional segments
are ‘chronically stunned’ (preserved perfusion and 18F-FDG uptake),
‘hibernating’ (impaired perfusion, preserved 18F-FDG uptake), or
‘scarred’ (impaired perfusion and 18F-FDG uptake).42 A pooled analysis
demonstrated sensitivity of 92% and specificity of 63% for 18F-FDG to
predict functional recovery following revascularization.43
PET-MR
As shown, MRI and PET use different biological approaches to assess
myocardial viability. To date, most studies have focussed on cross-
validation of techniques rather than exploitation of synergy.
Published studies have reported good agreement with LGE trans-
murality and 18F-FDG uptake with PET-MR in viability assess-
ment.9,44,45 In a study of patients prior to consideration for coronary
revascularization, PET-MR reclassified 19% of segments reported as
‘not assessable’ due to intermediate LGE (25–75% transmurality)
after integration of 18F-FDG.46 This led to a recommendation for
revascularization of only one additional coronary vessel compared
with MRI alone in 12 patients.46 MRI performed at 6 months follow-
up found that initial 18F-FDG was a better predictor for functional re-
covery than baseline LGE (Figure 1).44
Future outlook
Hybrid PET-MR offers potential for combined morphological, func-
tional, and metabolic assessment of myocardial viability. Hybrid PET-
MR may provide incremental diagnostic value particularly in cases
where MRI or PET alone provide intermediate probabilities of func-
tional recovery such as in cases with LGE of 25–75%. Furthermore, in
complex cases such as multivessel CAD and ischaemic cardiomyop-
athy, multimodal imaging may provide complementary information
to more accurately predict functional recovery. This could be
achieved in a single PET-MR scan by combining data on contractile
function with dobutamine stress cardiovascular magnetic resonance
and co-registration of 18F-FDG PET activity in addition to wall thick-
ness and LGE. Potential clinical utility will only be realized in larger
studies that define clear incremental benefit of patient outcomes.
Coronary imaging
Non-invasive coronary imaging is the domain of cardiac CT but both
MRI and PET provide relevant information on coronary arterial path-
ology, in particular atherosclerotic plaque, and their combination
holds promise for risk stratification.
MRI
Magnetic resonance angiography can visualize the proximal course of
coronary arteries in almost all cases47 and is recommended in guide-
lines for assessment of coronary artery anomalies and aortocoronary
bypass grafts but not detection of coronary stenosis.48 Coronary ves-
sel wall imaging with black-blood MRI demonstrates increased wall
thickness in CAD patients.49,50 Non-contrast T1-weighted images
visualized intracoronary thrombus with sensitivity 91% in patients fol-
lowing acute myocardial infarction.51 Furthermore, high-intensity pla-
ques identified by non-contrast T1-weighted images were an
independent factor for predicting coronary events.52
PET
Arterial 18F-FDG and increased carotid 18F-FDG uptake are associ-
ated with increased risk of adverse cardiovascular events.53,54
However, 18F-FDG coronary imaging is challenging as left ventricular
myocardial glucose uptake often obscures activity within coronary
vessels. There is growing interest into 18F-Fluoride, which has a predi-
lection for vascular microcalcification, a feature of high-risk ather-
oma.55 Coronary 18F-Fluoride uptake was demonstrated in patients
with high Framingham risk score and was localized in culprit lesions in
93% of patients following acute myocardial infarction.56,57 68Ga-
DOTATATE, a specific macrophage tracer, was detected in culprit
coronary lesions in patients with recent myocardial infarction or
high-risk stable lesions and was a better discriminator of high-risk ath-
erosclerotic lesions than 18F-FDG.58
PET-MR
The potential of hybrid PET-MR for coronary imaging has been dem-
onstrated in a number of feasibility studies.
Coronary PET-MR was performed with 18F-Fluoride or 18F-FDG
in 23 patients with CAD or risk factors for CAD.59 Several ‘hotspots’
of 18F-Fluoride were observed in the coronary arteries of patients
with established CAD and a novel AC method eliminated significant
artefacts compared with standard AC methods.59
Another study demonstrated greater 18F-Fluoride uptake com-
pared with non-culprit lesions on PET-MR following percutaneous
revascularization.60 Interestingly, 18F-Fluoride uptake was demon-
strated within infarcted myocardium, depicted from scar tissue, and
in coronary plaque.60 (Figure 2).
Future outlook
Clinical studies of PET-MR thus far have demonstrated techniques to
localize plaque rupture, although imaging was performed following
Hybrid PET-MR of the heart 965
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acute cardiac events. Of much greater clinical relevance is the ability
to localize and identify vulnerable plaques prior to rupture. Hybrid
PET-MR imaging is well suited to meet this challenge: anatomical de-
tail and plaque characterization can be obtained from MRI and com-
bined with inflammatory atherosclerotic plaque activity from PET.
Furthermore, emerging MRI motion models may be applied at mul-
tiple time points to motion-correct PET data and MRI data simultan-
eously without additional radiation.20 Emerging radiotracers (Table 2)
such as 18F-Fluoride and 68Ga-DOTATATE may be evaluated with
developing MRI motion correction techniques for precise anatomical
identification of high-risk coronary plaques prior to rupture. This may
allow targeted selection of high-risk patients for aggressive risk factor
modification or revascularization and prevent adverse outcome.
Cardiac sarcoidosis
Sarcoidosis is a multisystem granulomatous disorder that causes ar-
rhythmia, conduction disease, cardiac failure, or sudden cardiac
death. No universally accepted diagnostic test exists for cardiac
sarcoidosis and sensitivity of endomyocardial biopsy is around 20%.61
Diagnosis of cardiac sarcoidosis is challenging, and multimodality
imaging is recommended with MRI and PET in a recent international
position paper (Figure 3).62
MRI
Most commonly reported MRI findings in cardiac sarcoidosis include
LGE of the mid-wall/epicardium of basal septum and lateral wall, and
subendocardial and transmural enhancement.63 LGE in patients with
cardiac sarcoidosis was an independent predictor for ventricular
tachycardia and death.64,65 Patients (n= 61) with cardiac sarcoidosis
(biopsy confirmed or clinical criteria) were found to have greater T1,
T2, and ECV values compared with volunteers.66 A reduction in na-
tive T1 and T2 values was reported in 18 patients following anti-
inflammatory therapy.67 Parametric mapping may serve as an imaging
biomarker of disease activity and inflammation and guide anti-
inflammatory therapy rather than LGE, which indicates fibrosis and
may represent late sequelae or non-active disease.
Figure 1 Different combinations of 18F-FDG uptake and LGE transmurality with PET-MR. Left column: ‘PET viable/MRI viable’; middle column:
‘PET non-viable/MRI non-viable’; right column: ‘PET non-viable/MRI viable’. White arrows indicate infarcted myocardium. Reproduced with permis-
sion from ref. 44.
966 M.S. Nazir et al.
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PET
18F-FDG lends itself well to identification of inflammatory lesions in ac-
tive sarcoidosis as there is increased glucose utilization from macro-
phage activity. Careful patient preparation with low-carbohydrate diet
and fasting prior to imaging is essential to avoid false positive results.68
PET imaging for sarcoidosis includes imaging with a perfusion radio-
tracer and 18F-FDG uptake with three patterns recognized: normal per-
fusion and no 18F-FDG uptake, abnormal perfusion or 18F-FDG uptake,
and abnormal perfusion and metabolism.69 A perfusion-metabolism
mismatch (reduced perfusion and increased 18F-FDG uptake) was asso-
ciated with increased risk of cardiac death or ventricular arrhythmia.69
A meta-analysis demonstrated sensitivity of 89% and specificity of
78% for 18F-FDG to detect cardiac sarcoidosis compared with
Japanese Ministry of Health and Welfare (JMHW) criteria.70
PET-MR
Several studies have utilized PET-MR in patients with suspected car-
diac sarcoidosis.
In a study of 51 patients, the sensitivities for cardiac sarcoidosis
detection of PET and MRI alone were 85% and 82%, respectively,
which improved to 94% with hybrid PET-MR using the JMHW cri-
teria as reference standard in patients with suspected cardiac sar-
coidosis.71 There was poor agreement between regions of high
18F-FDG uptake and LGE, although this is not an unexpected find-
ing as the two modalities measure different entities of disease ac-
tivity, and this study highlights the complementary information
acquired from both modalities. At 2-year follow up, cardiac right
ventricular PET involvement and presence of LGE were independ-
ent predictors of adverse events.71
Figure 2 Subendocardial LGE demonstrating extensive infarct tissue (A) overlaid with 18F-Fluoride uptake indicating myocardial microcalcification
(B). Reproduced with permission from ref. 60.
Figure 3 Recommended strategy for non-invasive imaging for assessment of patients with suspected cardiac sarcoidosis. Reproduced with permis-
sion from ref. 62.
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In another study, PET-MR was used in 25 patients with sus-
pected active sarcoidosis, defined as positive LGE and 18F-FDG
uptake (Figure 4).72 Higher 18F-FDG SUV outperformed
T2-mapping by MRI (area under the curve 0.98 vs. 0.75, respect-
ively) for detection of active sarcoidosis.72 This study demon-
strated the utility of hybrid imaging to differentiate active cardiac
sarcoidosis from non-active disease with an alternative classifica-
tion, that may be more clinically meaningful compared with cur-
rent established diagnostic criteria.
Future outlook
Hybrid PET-MR combines two powerful imaging modalities to obtain
complementary information on distinct pathological processes in car-
diac sarcoidosis: 18F-FDG PET delineates acute myocardial inflamma-
tion from macrophage activity, whilst MRI reveals regional motion
wall abnormalities from granuloma formation, fibrosis from LGE, oe-
dema from T2, and changes in myocardial structure with parametric
mapping. The combination of precisely coregistered data in a single
scan may be used to devise and validate much needed accurate diag-
nostic criteria for cardiac sarcoidosis. Furthermore, hybrid PET-MR
may provide unique insights into the pathophysiology of cardiac sar-
coidosis and serve as an imaging biomarker to guide anti-
inflammatory therapy. Hybrid PET-MR may also derive perfusion-
metabolism information from MRI perfusion data and 18F-FDG activ-
ity at reduced radiation burden.
Myocarditis
Myocarditis is an inflammatory condition that causes chest pain, acute
or chronic heart failure, life threatening arrhythmias, or cardiogenic
shock.73 MRI is now commonly used in the diagnosis of myocarditis
and to differentiate from myocardial infarction, while PET can also
detect acute inflammation in myocarditis.
MRI
MRI provides important information in patients with myocarditis:
increased signal intensity with T2-weighted imaging in acute myocar-
ditis results from oedema, early gadolinium enhancement (EGE)
demonstrates capillary leakage and LGE identifies infiltration and scar,
typically in the inferolateral walls and less frequently in the
anteroseptum.74
The ‘Lake Louise’ Criteria (which are currently being revised)
requires two of three positive MRI features—EGE, LGE, and T2 imag-
ing.74 In addition, native T1-mapping may be used and in a study 50
patients had superior diagnostic performance compared with T2-
weighted imaging in patients with suspected myocarditis.75
Furthermore, native T1 provided incremental diagnostic value and out-
performed the original Lake-Louise criteria in acute myocarditis.76
PET
18F-FDG is highly sensitive to metabolically active inflammation.77
18F-FDG had sensitivity and specificity of 100% for detection of endo-
myocardial biopsy proven active myocarditis in patients when per-
formed within 14 days of onset.78 Another study demonstrated
increased uptake of 68Ga-DOTA-TOC in patients when PET-CT
performed within 3–10 days of symptom onset.79
PET-MR
In the only study of simultaneous PET-MR in patients (n= 55) with
suspected myocarditis, there was good agreement between 18F-FDG
and T2 and/or LGE (Figure 5).80 However, no EGE imaging was per-
formed, nor did patients undergo endomyocardial biopsy as a refer-
ence standard. 18F-FDG may provide additive information in patients
with diffuse myocardial damage not detectable by MRI in diffuse in-
flammation or before myocyte necrosis.
Future outlook
A study of combined parametric mapping and 18F-FDG has yet to be
performed, which will be of greater value for cross-validation.
Moreover, PET-MR may aid in staging and risk stratification of
patients with myocarditis by combining inflammatory activity with
PET 18F-FDG or novel tracers such as 68Ga-DOTA-TOC with MRI
assessment of fibrosis and oedema. In addition, PET-MR may guide bi-
opsy of inflammatory foci with high metabolic activity through precise
anatomical localization by MRI.81
Amyloidosis
Cardiac amyloidosis is an infiltrative condition characterized by
deposition of beta-pleated sheets and causes restrictive cardiomyop-
athy. Differentiation of light-chain amyloid (AL) or wild type/familial-
related amyloid (ATTR) is important as treatment and prognosis
differ.
MRI
Typical MRI findings in amyloidosis include symmetric or asymmetric
left ventricular thickening, biatrial enlargement, and pleural effusions.
LGE shows global transmural or subendocardial LGE in non-
coronary artery territory distribution82 and had sensitivity of 85%
and specificity of 92% for detection of cardiac amyloid in a recent
meta-analysis.83 Transmural LGE was an independent marker for
mortality in patients with cardiac amyloid.84 Native T1-values are ele-
vated in ATTR amyloid patients compared with volunteers and
patients with hypertrophic cardiomyopathy.85
PET
11C-Pittsburgh B, a radiotracer for detection of beta-amyloid deposits
in Alzheimer’s patients, was detected in 13/15 patients with biopsy
confirmed cardiac amyloid, whereas none was detected in patients
without amyloid.86 18F-Florbetapir also detects beta-amyloid plaques
and a pilot study demonstrated greater uptake in patients with car-
diac amyloid compared with controls.87,88
PET-MR
Only one published study to date has explored PET-MR in cardiac
amyloid. Seven patients with AL or ATTR amyloid and 7 controls
underwent PET-MR imaging.89 T1 values were similar between AL
and ATTR amyloid. Fused and co-registered images allowed precise
measurement of tissue 18F-Fluoride activity in areas of myocardial
amyloid deposition depicted by LGE. ATTR amyloid patients had
higher tissue-to-background ratios of 18F-Fluoride uptake compared
with AL amyloid patients or controls.89
968 M.S. Nazir et al.
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Future outlook
Hybrid PET-MR may have a role in the future to discriminate AL and
ATTR amyloid heart disease, although larger clinical studies are
required prior to consideration as a routine clinical application.
Anderson-Fabry disease
Anderson-Fabry disease (AFD), an X-linked lysosomal storage dis-
order characterized by deficiency of alpha-galactosidase, results in
glycosphingolipids accumulation and may cause left ventricular hyper-
trophy (LVH), myocardial fibrosis, systolic and diastolic dysfunction,
arrhythmia, conduction disease, and sudden death.90 Early diagnosis
is important as enzyme replacement therapy (EZT) can reverse dis-
ease progression.91
MRI
Typical MRI findings in AFD include concentric, asymmetric, or apical
LVH and mid-wall fibrosis of the basal inferolateral wall.92,93 Native
Figure 4 Imaging active cardiac sarcoidosis. Left panel: Late gadolinium enhancement (LGE) MRI. Right panel: Hybrid LGE and 18F-fluorodeoxyglu-
cose (18F-FDG). (A) Subepicardial LGE in basal anteroseptum extending into right ventricular free wall and increased 18F-FDG uptake at same region
on fused PET-MR. (B) Subepicardial LGE in the basal anterolateral wall with increased 18F-FDG uptake co-localizing to identical region on PET-MR.
(C) Patchy midwall LGE in anterolateral wall with matched increased 18F-FDG uptake on PET-MR. (D) Multifocal LGE in lateral wall with matched
increased 18F-FDG uptake on PET-MR. Reproduced with permission from ref. 72.
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..T1-mapping can add to the detection of AFD since lipids lower
T1-values and accurately discriminate AFD from other causes of
LVH such as hypertrophic cardiomyopathy, aortic stenosis, and
hypertension.94
PET
Two studies reported that AFD patients had lower MPR with
15O-Water compared with controls.95,96 This may relate to
increased vascular resistance secondary to cardiac myocyte hyper-
trophy and fibrosis due to intracellular glycosphingolipids accumula-
tion. Accumulating glycolipids may trigger an inflammatory response
with pro-inflammatory cytokines and increased macrophage activity
that eventually lead to fibrotic changes.97 PET may have a role to po-
tentially detect inflammation at early stages of disease.
PET-MR
In a study of 13 patients with AFD who underwent PET-MR, 5
patients had LVH and focal LGE fibrosis of which 3 had positive STIR
and focal 18F-FDG uptake.98 The latter group had raised cardiac
troponin levels, whilst those patients with negative STIR images did
not have focal 18F-FDG uptake. The authors suggested PET-MR dif-
ferentiated mature fibrosis or scar from fibrosis associated to active
inflammation. However, this was a small sample size and several
patients had homogenous 18F-FDG uptake, possibly indicating insuffi-
cient myocardial suppression.
Future outlook
PET-MR may aid diagnosis of AFD, provide insights into immunopa-
thology of different disease stages and have potential as an imaging
biomarker to guide EZT.
Cardiac masses
In clinical practice, cardiac masses are primarily imaged with echocar-
diography and CT, while MRI and PET are reserved for further
characterization.
MRI
MRI can interrogate cardiac masses with T1-weighted black-
blood imaging for mass localization, cine imaging for morph-
ology, mobility and functional consequence, and tagging for
assessment of attachments to other structures.99 T1 and T2-
weighted imaging with/without fat suppression aids further
tissue characterization.99 Furthermore, EGE allows thrombus
detection, LGE allows assessment of extracellular matrix, whilst
perfusion allows vascularity assessment. MRI has diagnostic ac-
curacy of 92% for prediction of lesion type compared with hist-
ology findings.100 LGE can differentiate benign and malignant
tumours with diagnostic accuracy of 79%.101
Figure 5 PET-MR images in myocarditis. Inferolateral wall mid-wall fibrosis (MRI) (A), homogenous T2 signal intensity (MRI) (B). Increased
18F-FDG signal in the inferolateral wall (PET) (C). Fused PET-MR with increased 18F-FDG uptake at the site of inferolateral LGE (D). Reproduced with
permission from ref. 80.
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PET
PET allows whole body evaluation of masses with 18F-FDG uptake
for staging, monitoring therapy, and prognosis. Malignant tumours
have greater 18F-FDG uptake compared with benign tumours.102 The
diagnostic accuracy for detection of malignant lesions was 96%, with
SUVmax cut-off of 3.5–4.0.
103
PET-MR
In a study of 20 patients who underwent PET-MR for cardiac mass as-
sessment, 18F-FDG SUVmax was higher in malignant lesions and SUVmax
cut-off of 5.2 provided 100% sensitivity and 92% specificity for malig-
nancy detection.104 Similarly, a 100% sensitivity and 92% specificity was
achieved for MRI to detect malignancy, using combined cine imaging,
T1-weighted, T2-weighted, post-contrast T1-weighted images and
presence of pericardial effusion.104 A hybrid approach of MRI and PET
with SUVmax cut-off of 5.2 increased sensitivity and specificity to 100%.
These are interesting findings, although first-pass perfusion, EGE or
LGE imaging was not reported as part of the ‘MRI only’ classification,
which may have otherwise increased diagnostic accuracy for MRI alone.
Future outlook
Hybrid PET-MR can offer additional information though precise co-
registration and localization of masses to be undertaken, with
detailed interrogation with high resolution T1 and T2-weighted
images, parametric mapping, perfusion, LGE imaging and 18F-FDG up-
take in one sitting that may improve diagnosis, staging and provide
further clarity on disease activity.
Future perspectives
PET-MR is an emerging modality gaining widespread interest for ap-
plication to cardiovascular disease.
The ability to obtain multiple radiation-free MRI data to motion-
correct PET data is highly attractive, and future research will focus on
improved efficiency and reduction in acquisition time of MRI sequen-
ces to simultaneously enhance PET images, quantitative PET data as
well as MRI data, particularly for coronary imaging and the application
of emerging radiotracers.
AC has long been a challenge for PET-MR and novel methods to de-
velop highly accurate AC maps such as with the inclusion of bone seg-
mentation may be applied in future studies.14 Manual methods for
misalignment of AC maps allows correction and studies thus far have
demonstrated PET-MR provides comparable quantitative data to PET-
CT. Another pressing challenge is a solution for AC map signal drop-
out from metallic artefacts, which may become increasingly important
in the future with emerging MRI compatible implantable cardiac devices
at 3 T,105 the field strength of available clinical PET-MR systems.
PET-MR is an expensive modality that requires proximity to a cyclo-
tron, specialist staff trained in PET and MRI for patient preparation,
image acquisition, AC, post-processing, analysis and reporting.
Simultaneous PET-MR imaging may improve patient workflow, with
improved patient experience of a single scan. However, clear clinical
indications for a hybrid PET-MR scan require evidence of incremental
benefit compared with sequential imaging with separate MRI and PET
scans. There is vast potential for application to research for cardiac PET-
MR, particularly for coronary imaging which may pave the way for
multicentre studies for identification of high-risk vulnerable plaques prior
to rupture. With the current evidence available, clinical PET-MR may be
well suited to conditions such as cardiac masses and suspected cardiac
sarcoidosis where hybrid imaging offers precise co-registration and fu-
sion of complementary information that may provide incremental value.
Once clear clinical indications and pathways are developed, these
will need to be recognized as cost-effective for healthcare systems
with a defined route for reimbursement.
Conclusion
Hybrid PET-MR combines two powerful imaging modalities to fuse and
co-register anatomical detail, tissue characterization, and metabolic
data. Technical challenges with AC remain and there is large potential
for motion correction of PET data from MRI data. Several studies thus
far have focussed on cross-validation of techniques and emerging stud-
ies indicate incremental benefit beyond sequential MRI and PET imag-
ing. Future large studies will determine incremental utility of combined
rather than sequential imaging and whether PET-MR will be restricted
to the research domain or cement itself in the clinical arena.
Funding
The authors acknowledge financial support from the Department of
Health through the National Institute for Health Research (NIHR) com-
prehensive Biomedical Research Centre award to Guy’s & St Thomas’
NHS Foundation Trust in partnership with King’s College London and
King’s College Hospital NHS Foundation Trust and by the NIHR
Healthcare Technology Co-operative for Cardiovascular Disease at Guy’s
and St Thomas’ NHS Foundation Trust. This work was supported by the
Wellcome/EPSRC Centre for Medical Engineering [WT 203148/Z/16/Z].
M.S.N. was funded by the UK Medical Research Council under grant
number MR/P01979X/1. S.P. was funded by a British Heart Foundation
Chair under grant number CH/16/2/32089. The views expressed are
those of the authors and not necessarily those of the NHS, the NIHR,
the DoH, EPSRC, MRC or the Wellcome Trust.
Conflict of interest: None declared.
References
1. Messroghli DR, Moon JC, Ferreira VM, Grosse-Wortmann L, He T, Kellman P et al.
Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2,
T2* and extracellular volume: a consensus statement by the Society for
Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association
for Cardiovascular Imaging (EACVI). J Cardiovasc Magn Reson 2017;19:75.
2. Vandenberghe S, Marsden PK. PET-MRI: a review of challenges and solutions in
the development of integrated multimodality imaging. Phys Med Biol 2015;60:
R115–54.
3. Muzic RF, DiFilippo FP. PET/MRI—Technical Review. Semin Roentgenol 2014;49:
242–54.
4. Kinahan PE, Townsend DW, Beyer T, Sashin D. Attenuation correction for a
combined 3D PET/CT scanner. Med Phys 1998;25:2046–53.
5. Keereman V, Mollet P, Berker Y, Schulz V, Vandenberghe S. Challenges and cur-
rent methods for attenuation correction in PET/MR. MAGMA 2013;26:81–98.
6. Dixon WT. Simple proton spectroscopic imaging. Radiology 1984;153:189–94.
7. Martinez-Moller A, Souvatzoglou M, Delso G, Bundschuh RA, Chefd’hotel C,
Ziegler SI et al. Tissue classification as a potential approach for attenuation cor-
rection in whole-body PET/MRI: evaluation with PET/CT data. J Nucl Med 2009;
50:520–6.
8. Keereman V, Fierens Y, Broux T, De Deene Y, Lonneux M, Vandenberghe S.
MRI-based attenuation correction for PET/MRI using ultrashort echo time
sequences. J Nucl Med 2010;51:812–8.
9. Nensa F, Poeppel TD, Beiderwellen K, Schelhorn J, Mahabadi AA, Erbel R et al.
Hybrid PET/MR imaging of the heart: feasibility and initial results. Radiology
2013;268:366.
Hybrid PET-MR of the heart 971
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
10. Oldan JD, Shah SN, Brunken RC, DiFilippo FP, Obuchowski NA, Bolen MA. Do
myocardial PET-MR and PET-CT FDG images provide comparable information?
J Nucl Cardiol 2016;23:1102.
11. Vontobel J, Liga R, Possner M, Clerc OF, Mikulicic F, Veit-Haibach P et al. MR-
based attenuation correction for cardiac FDG PET on a hybrid PET/MRI scan-
ner: comparison with standard CT attenuation correction. Eur J Nucl Med Mol
Imaging 2015;42:1574–80.
12. Lau JMC, Laforest R, Sotoudeh H, Nie X, Sharma S, McConathy J et al.
Evaluation of attenuation correction in cardiac PET using PET/MR. J Nucl Cardiol
2017;24:839–46.
13. Lassen ML, Rasul S, Beitzke D, Stelzmuller ME, Cal-Gonzalez J, Hacker M et al.
Assessment of attenuation correction for myocardial PET imaging using com-
bined PET/MRI. J Nucl Cardiol 2017. https://doi.org/10.1007/s12350-017-1118-2.
14. Paulus DH, Quick HH, Geppert C, Fenchel M, Zhan Y, Hermosillo G et al.
Whole-body PET/MR imaging: quantitative evaluation of a novel model-based
MR attenuation correction method including bone. J Nucl Med 2015;56:
1061–6.
15. Berker Y, Franke J, Salomon A, Palmowski M, Donker HC, Temur Y et al. MRI-
based attenuation correction for hybrid PET/MRI systems: a 4-class tissue
segmentation technique using a combined ultrashort-echo-time/Dixon MRI se-
quence. J Nucl Med 2012;53:796–804.
16. Furst S, Grimm R, Hong I, Souvatzoglou M, Casey ME, Schwaiger M et al.
Motion correction strategies for integrated PET/MR. J Nucl Med 2015;56:261–9.
17. Fayad H, Schmidt H, Wuerslin C, Visvikis D. Reconstruction-incorporated re-
spiratory motion correction in clinical simultaneous PET/MR imaging for oncol-
ogy applications. J Nucl Med 2015;56:884–9.
18. Grimm R, Furst S, Souvatzoglou M, Forman C, Hutter J, Dregely I et al. Self-
gated MRI motion modeling for respiratory motion compensation in integrated
PET/MRI. Med Image Anal 2015;19:110–20.
19. Kolbitsch C, Ahlman MA, Davies-Venn C, Evers R, Hansen M, Peressutti D
et al. Cardiac and respiratory motion correction for simultaneous cardiac PET/
MR. J Nucl Med 2017;58:846–52.
20. Munoz C, Neji R, Cruz G, Mallia A, Jeljeli S, Reader AJ et al. Motion-corrected
simultaneous cardiac positron emission tomography and coronary MR angiog-
raphy with high acquisition efficiency. Magn Reson Med 2018;79:339–50.
21. Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A et al.
2013 ESC guidelines on the management of stable coronary artery disease: the
Task Force on the management of stable coronary artery disease of the
European Society of Cardiology. Eur Heart J 2013;34:2949–3003.
22. Takx RA, Blomberg BA, El Aidi H, Habets J, de Jong PA, Nagel E et al.
Diagnostic accuracy of stress myocardial perfusion imaging compared to inva-
sive coronary angiography with fractional flow reserve meta-analysis. Circ
Cardiovasc Imaging 2015;8:e002666.
23. Sammut EC, Villa ADM, Di Giovine G, Dancy L, Bosio F, Gibbs T et al.
Prognostic value of quantitative stress perfusion cardiac magnetic resonance.
JACC Cardiovasc Imaging 2018;11:686–94.
24. Kellman P, Hansen MS, Nielles-Vallespin S, Nickander J, Themudo R, Ugander
M et al. Myocardial perfusion cardiovascular magnetic resonance: optimized
dual sequence and reconstruction for quantification. J Cardiovasc Magn Reson
2017;19:43.
25. Engblom H, Xue H, Akil S, Carlsson M, Hindorf C, Oddstig J et al. Fully quanti-
tative cardiovascular magnetic resonance myocardial perfusion ready for clinical
use: a comparison between cardiovascular magnetic resonance imaging and
positron emission tomography. J Cardiovasc Magn Reson 2017;19:78.
26. Klein R, Beanlands RS, deKemp RA. Quantification of myocardial blood flow
and flow reserve: technical aspects. J Nucl Cardiol 2010;17:555–70.
27. Bol A, Melin JA, Vanoverschelde JL, Baudhuin T, Vogelaers D, De Pauw M et al.
Direct comparison of 13N ammonia and 15O water estimates of perfusion
with quantification of regional myocardial blood flow by microspheres.
Circulation 1993;87:512.
28. Nitzsche EU, Choi Y, Czernin J, Hoh CK, Huang SC, Schelbert HR. Noninvasive
quantification of myocardial blood flow in humans. A direct comparison of the
[13N]ammonia and the [15O]water techniques. Circulation 1996;93:2000–6.
29. Nandalur KR, Dwamena BA, Choudhri AF, Nandalur SR, Reddy P, Carlos RC.
Diagnostic performance of positron emission tomography in the detection of
coronary artery disease: a meta-analysis. Acad Radiol 2008;15:444.
30. Dorbala S, Hachamovitch R, Curillova Z, Thomas D, Vangala D, Kwong RY
et al. Incremental prognostic value of gated Rb-82 positron emission tomog-
raphy myocardial perfusion imaging over clinical variables and rest LVEF. JACC
Cardiovasc Imaging 2009;2:846–54.
31. Yoshinaga K, Chow BJ, Williams K, Chen L, deKemp RA, Garrard L et al. What
is the prognostic value of myocardial perfusion imaging using rubidium-82 posi-
tron emission tomography? J Am Coll Cardiol 2006;48:1029.
32. Bratis K, Mahmoud I, Chiribiri A, Nagel E. Quantitative myocardial perfusion
imaging by cardiovascular magnetic resonance and positron emission tomog-
raphy. J Nucl Cardiol 2013;20:860–70.
33. Kajander SA, Joutsiniemi E, Saraste M, Pietila M, Ukkonen H, Saraste A et al.
Clinical value of absolute quantification of myocardial perfusion with (15)O-
water in coronary artery disease. Circ Cardiovasc Imaging 2011;4:678–84.
34. Ziadi MC, Dekemp RA, Williams K, Guo A, Renaud JM, Chow BJ et al. Does
quantification of myocardial flow reserve using rubidium-82 positron emission
tomography facilitate detection of multivessel coronary artery disease? J Nucl
Cardiol 2012;19:670–80.
35. Graf S, Khorsand A, Gwechenberger M, Novotny C, Kletter K, Sochor H
et al. Typical chest pain and normal coronary angiogram: cardiac risk factor
analysis versus PET for detection of microvascular disease. J Nucl Med 2007;
48:175–81.
36. Ziadi MC, Dekemp RA, Williams KA, Guo A, Chow BJ, Renaud JM et al.
Impaired myocardial flow reserve on rubidium-82 positron emission tomog-
raphy imaging predicts adverse outcomes in patients assessed for myocardial is-
chemia. J Am Coll Cardiol 2011;58:740.
37. Fukushima K, Javadi MS, Higuchi T, Lautamaki R, Merrill J, Nekolla SG et al.
Prediction of short-term cardiovascular events using quantification of global
myocardial flow reserve in patients referred for clinical 82Rb PET perfusion
imaging. J Nucl Med 2011;52:726–32.
38. Kunze KP, Nekolla SG, Rischpler C, Zhang SH, Hayes C, Langwieser N et al.
Myocardial perfusion quantification using simultaneously acquired (13) NH3-
ammonia PET and dynamic contrast-enhanced MRI in patients at rest and stress.
Magn Reson Med 2018. https://doi.org/10.1002/mrm.27213.
39. Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O et al. The use of
contrast-enhanced magnetic resonance imaging to identify reversible myocardial
dysfunction. N Engl J Med 2000;343:1445–53.
40. Romero J, Xue X, Gonzalez W, Garcia MJ. CMR imaging assessing viability in
patients with chronic ventricular dysfunction due to coronary artery disease: a
meta-analysis of prospective trials. JACC Cardiovasc Imaging 2012;5:494–508.
41. Camici PG. Positron emission tomography and myocardial imaging. Heart 2000;
83:475–80.
42. Schinkel AFL, Poldermans D, Elhendy A, Bax JJ. Assessment of myocardial viabil-
ity in patients with heart failure. J Nucl Med 2007;48:1135–46.
43. Schinkel AF, Bax JJ, Poldermans D, Elhendy A, Ferrari R, Rahimtoola SH.
Hibernating myocardium: diagnosis and patient outcomes. Curr Probl Cardiol
2007;32:375.
44. Rischpler C, Langwieser N, Souvatzoglou M, Batrice A, van Marwick S, Snajberk
J et al. PET/MRI early after myocardial infarction: evaluation of viability with late
gadolinium enhancement transmurality vs. 18F-FDG uptake. Eur Heart J
Cardiovasc Imaging 2015;16:661–9.
45. Rischpler C, Dirschinger RJ, Nekolla SG, Kossmann H, Nicolosi S, Hanus F et al.
Prospective evaluation of 18F-Fluorodeoxyglucose uptake in postischemic myo-
cardium by simultaneous positron emission tomography/magnetic resonance
imaging as a prognostic marker of functional outcome. Circ Cardiovasc Imaging
2016;9:e004316.
46. Priamo J, Adamopoulos D, Rager O, Frei A, Noble S, Carballo D et al.
Downstream indication to revascularization following hybrid cardiac PET/MRI:
preliminary results. Nucl Med Commun 2017;38:515.
47. Chiribiri A, Botnar RM, Nagel E. Magnetic resonance coronary angiography:
where are we today? Curr Cardiol Rep 2013;15:328.
48. Hundley WG, Bluemke DA, Finn JP, Flamm SD, Fogel MA, Friedrich MG et al.
ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardio-
vascular magnetic resonance: a report of the American College of Cardiology
Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol
2010;55:2614–62.
49. Kim WY, Stuber M, Bornert P, Kissinger KV, Manning WJ, Botnar RM. Three-di-
mensional black-blood cardiac magnetic resonance coronary vessel wall imaging
detects positive arterial remodeling in patients with nonsignificant coronary ar-
tery disease. Circulation 2002;106:296–9.
50. Fayad ZA, Fuster V, Fallon JT, Jayasundera T, Worthley SG, Helft G et al.
Noninvasive in vivo human coronary artery lumen and wall imaging using black-
blood magnetic resonance imaging. Circulation 2000;102:506–10.
51. Jansen CH, Perera D, Makowski MR, Wiethoff AJ, Phinikaridou A, Razavi RM
et al. Detection of intracoronary thrombus by magnetic resonance imaging in
patients with acute myocardial infarction. Circulation 2011;124:416–24.
52. Noguchi T, Kawasaki T, Tanaka A, Yasuda S, Goto Y, Ishihara M et al. High-in-
tensity signals in coronary plaques on noncontrast T1-weighted magnetic res-
onance imaging as a novel determinant of coronary events. J Am Coll Cardiol
2014;63:989–99.
53. Figueroa AL, Abdelbaky A, Truong QA, Corsini E, MacNabb MH, Lavender
ZR et al. Measurement of arterial activity on routine FDG PET/CT images
improves prediction of risk of future CV events. JACC Cardiovasc Imaging 2013;
6:1250–9.
54. Moon SH, Cho YS, Noh TS, Choi JY, Kim BT, Lee KH. Carotid FDG uptake
improves prediction of future cardiovascular events in asymptomatic individuals.
JACC Cardiovasc Imaging 2015;8:949–56.
972 M.S. Nazir et al.
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
55. Irkle A, Vesey AT, Lewis DY, Skepper JN, Bird JL, Dweck MR et al. Identifying
active vascular microcalcification by (18)F-sodium fluoride positron emission
tomography. Nat Commun 2015;6:7495.
56. Dweck MR, Chow MW, Joshi NV, Williams MC, Jones C, Fletcher AM et al.
Coronary arterial 18F-sodium fluoride uptake: a novel marker of plaque biol-
ogy. J Am Coll Cardiol 2012;59:1539–48.
57. Joshi NV, Vesey AT, Williams MC, Shah AS, Calvert PA, Craighead FH et al.
18F-fluoride positron emission tomography for identification of ruptured and
high-risk coronary atherosclerotic plaques: a prospective clinical trial. Lancet
2014;383:705–13.
58. Tarkin JM, Joshi FR, Evans NR, Chowdhury MM, Figg NL, Shah AV et al.
Detection of atherosclerotic inflammation by (68)Ga-DOTATATE PET com-
pared to [(18)F]FDG PET imaging. J Am Coll Cardiol 2017;69:1774–91.
59. Robson PM, Dweck MR, Trivieri MG, Abgral R, Karakatsanis NA, Contreras J
et al. Coronary artery PET/MR imaging: feasibility, limitations, and solutions.
JACC Cardiovasc Imaging 2017;10:1103–12.
60. Marchesseau S, Seneviratna A, Sjoholm AT, Qin DL, Ho JXM, Hausenloy DJ
et al. Hybrid PET/CT and PET/MRI imaging of vulnerable coronary plaque and
myocardial scar tissue in acute myocardial infarction. J Nucl Cardiol 2017. https:
//doi.org/10.1007/s12350-017-0918-8.
61. Uemura A, Morimoto S, Hiramitsu S, Kato Y, Ito T, Hishida H. Histologic diag-
nostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies. Am
Heart J 1999;138:299.
62. A joint procedural position statement on imaging in cardiac sarcoidosis: from
the Cardiovascular and Inflammation & Infection Committees of the European
Association of Nuclear Medicine, the European Association of Cardiovascular
Imaging, and the American Society of Nuclear Cardiology. Eur Heart J Cardiovasc
Imaging 2017;18:1073–89.
63. Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA et al.
Detection of myocardial damage in patients with sarcoidosis. Circulation 2009;
120:1969.
64. Murtagh G, Laffin LJ, Beshai JF, Maffessanti F, Bonham CA, Patel AV et al.
Prognosis of myocardial damage in sarcoidosis patients with preserved left ven-
tricular ejection fraction: risk stratification using. Circ Cardiovasc Imaging 2016;9:
e003738.
65. Hulten E, Agarwal V, Cahill M, Cole G, Vita T, Parrish S et al. Presence of late
gadolinium enhancement by cardiac magnetic resonance among patients with
suspected cardiac sarcoidosis is associated with adverse cardiovascular progno-
sis: a systematic review and meta-analysis. Circ Cardiovasc Imaging 2016;9:
e005001.
66. Greulich S, Kitterer D, Latus J, Aguor E, Steubing H, Kaesemann P et al.
Comprehensive cardiovascular magnetic resonance assessment in patients with
sarcoidosis and preserved left ventricular ejection fraction. Circ Cardiovasc
Imaging 2016;9:e005022.
67. Puntmann VO, Isted A, Hinojar R, Foote L, Carr-White G, Nagel E. T1 and T2
mapping in recognition of early cardiac involvement in systemic sarcoidosis.
Radiology 2017;285:63–72.
68. Dorbala S, Di Carli MF, Delbeke D, Abbara S, DePuey EG, Dilsizian V et al.
SNMMI/ASNC/SCCT guideline for cardiac SPECT/CT and PET/CT 1.0. J Nucl
Med 2013;54:1485–507.
69. Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL et al. Cardiac
positron emission tomography enhances prognostic assessments of patients
with suspected cardiac sarcoidosis. J Am Coll Cardiol 2014;63:329–36.
70. Youssef G, Leung E, Mylonas I, Nery P, Williams K, Wisenberg G et al. The use
of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and
metaanalysis including the Ontario experience. J Nucl Med 2012;53:241–8.
71. Wicks EC, Menezes LJ, Barnes A, Mohiddin SA, Sekhri N, Porter JC et al.
Diagnostic accuracy and prognostic value of simultaneous hybrid 18F-fluoro-
deoxyglucose positron emission tomography/magnetic resonance imaging in
cardiac sarcoidosis. Eur Heart J Cardiovasc Imaging 2018;19:757–67.
72. Dweck MR, Abgral R, Trivieri MG, Robson PM, Karakatsanis N, Mani V et al.
Hybrid magnetic resonance imaging and positron emission tomography with flu-
orodeoxyglucose to diagnose active cardiac sarcoidosis. JACC Cardiovasc Imaging
2018;11:94–107.
73. Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB et al.
Current state of knowledge on aetiology, diagnosis, management, and therapy
of myocarditis: a position statement of the European Society of Cardiology
Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013;34:
2636.
74. Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT
et al. Cardiovascular magnetic resonance in myocarditis: a JACC white paper.
J Am Coll Cardiol 2009;53:1475.
75. Ferreira VM, Piechnik SK, Dall’Armellina E, Karamitsos TD, Francis JM, Ntusi N
et al. T1 mapping for the diagnosis of acute myocarditis using CMR: comparison
to T2-weighted and late gadolinium enhanced imaging. JACC Cardiovasc Imaging
2013;6:1048–58.
76. Lurz P, Luecke C, Eitel I, Fohrenbach F, Frank C, Grothoff M et al.
Comprehensive cardiac magnetic resonance imaging in patients with suspected
myocarditis: the MyoRacer-Trial. J Am Coll Cardiol 2016;67:1800–11.
77. Jamar F, Buscombe J, Chiti A, Christian PE, Delbeke D, Donohoe KJ et al.
EANM/SNMMI guideline for 18F-FDG use in inflammation and infection. J Nucl
Med 2013;54:647–58.
78. Ozawa K, Funabashi N, Daimon M, Takaoka H, Takano H, Uehara M et al.
Determination of optimum periods between onset of suspected acute myo-
carditis and 18F-fluorodeoxyglucose positron emission tomography in the
diagnosis of inflammatory left ventricular myocardium. Int J Cardiol 2013;169:
196–200.
79. Lapa C, Reiter T, Li X, Werner RA, Samnick S, Jahns R et al. Imaging of myocar-
dial inflammation with somatostatin receptor based PET/CT—a comparison to
cardiac MRI. Int J Cardiol 2015;194:44–9.
80. Nensa F, Kloth J, Tezgah E, Poeppel TD, Heusch P, Goebel J et al. Feasibility of
FDG-PET in myocarditis: comparison to CMR using integrated PET/MRI. J Nucl
Cardiol 2018;25:785–94.
81. Juneau D, Erthal F, Alzahrani A, Alenazy A, Nery PB, Beanlands RS et al.
Systemic and inflammatory disorders involving the heart: the role of PET imag-
ing. Q J Nucl Med Mol Imaging 2016;60:383–96.
82. Syed IS, Glockner JF, Feng D, Araoz PA, Martinez MW, Edwards WD et al.
Role of cardiac magnetic resonance imaging in the detection of cardiac amyloid-
osis. JACC Cardiovasc Imaging 2010;3:155–64.
83. Zhao L, Tian Z, Fang Q. Diagnostic accuracy of cardiovascular magnetic reson-
ance for patients with suspected cardiac amyloidosis: a systematic review and
meta-analysis. BMC Cardiovasc Disord 2016;16:129.
84. Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banypersad SM et al.
Prognostic value of late gadolinium enhancement cardiovascular magnetic res-
onance in cardiac amyloidosis. Circulation 2015;132:1570–9.
85. Fontana M, Banypersad SM, Treibel TA, Maestrini V, Sado DM, White SK et al.
Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging 2014;7:
157–65.
86. Lee SP, Lee ES, Choi H, Im HJ, Koh Y, Lee MH et al. 11C-Pittsburgh B PET
imaging in cardiac amyloidosis. JACC Cardiovasc Imaging 2015;8:50–9.
87. Dorbala S, Vangala D, Semer J, Strader C, Bruyere JR Jr, Di Carli MF et al.
Imaging cardiac amyloidosis: a pilot study using (1)(8)F-florbetapir positron
emission tomography. Eur J Nucl Med Mol Imaging 2014;41:1652–62.
88. Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G et al. Amyloid
imaging with (18)F-florbetaben in Alzheimer disease and other
dementias. J Nucl Med 2011;52:1210–7.
89. Trivieri MG, Dweck MR, Abgral R, Robson PM, Karakatsanis NA, Lala A et al.
18F-Sodium Fluoride PET/MR for the assessment of cardiac amyloidosis. J Am
Coll Cardiol 2016;68:2712–4.
90. Linhart A, Elliott PM. The heart in Anderson-Fabry disease and other lysosomal
storage disorders. Heart 2007;93:528–35.
91. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S et al. Safety and
efficacy of recombinant human alpha-galactosidase A replacement therapy in
Fabry’s disease. N Engl J Med 2001;345:9–16.
92. Deva DP, Hanneman K, Li Q, Ng MY, Wasim S, Morel C et al. Cardiovascular
magnetic resonance demonstration of the spectrum of morphological pheno-
types and patterns of myocardial scarring in Anderson-Fabry disease. J
Cardiovasc Magn Reson 2016;18:14.
93. Moon JC, Sachdev B, Elkington AG, McKenna WJ, Mehta A, Pennell DJ et al.
Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry
disease. Evidence for a disease specific abnormality of the myocardial intersti-
tium. Eur Heart J 2003;24:2151–5.
94. Sado DM, White SK, Piechnik SK, Banypersad SM, Treibel T, Captur G et al.
Identification and assessment of Anderson-Fabry disease by cardiovascular mag-
netic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging
2013;6:392–8.
95. Kalliokoski RJ, Kalliokoski KK, Sundell J, Engblom E, Penttinen M, Kantola I et al.
Impaired myocardial perfusion reserve but preserved peripheral endothelial
function in patients with Fabry disease. J Inherit Metab Dis 2005;28:563–73.
96. Elliott PM, Kindler H, Shah JS, Sachdev B, Rimoldi OE, Thaman R et al.
Coronary microvascular dysfunction in male patients with Anderson-Fabry dis-
ease and the effect of treatment with alpha galactosidase A. Heart 2006;92:
357–60.
97. Rozenfeld P, Feriozzi S. Contribution of inflammatory pathways to Fabry dis-
ease pathogenesis. Mol Genet Metab 2017;122:19–27.
98. Nappi C, Altiero M, Imbriaco M, Nicolai E, Giudice CA, Aiello M et al. First ex-
perience of simultaneous PET/MRI for the early detection of cardiac involve-
ment in patients with Anderson-Fabry disease. Eur J Nucl Med Mol Imaging 2015;
42:1025–31.
99. Motwani M, Kidambi A, Herzog BA, Uddin A, Greenwood JP, Plein S. MR imag-
ing of cardiac tumors and masses: a review of methods and clinical applications.
Radiology 2013;268:26–43.
Hybrid PET-MR of the heart 973
..
..
..
..
..
..
..
..
..
..
..100. Hoffmann U, Globits S, Schima W, Loewe C, Puig S, Oberhuber G et al.
Usefulness of magnetic resonance imaging of cardiac and paracardiac masses.
Am J Cardiol 2003;92:890–5.
101. Pazos-Lo´pez P, Pozo E, Siqueira ME, Garcı´a-Lunar I, Cham M, Jacobi A et al.
Value of CMR for the differential diagnosis of cardiac masses. JACC Cardiovasc
Imaging 2014;7:896–905.
102. Rahbar K, Seifarth H, Schafers M, Stegger L, Hoffmeier A, Spieker T et al.
Differentiation of malignant and benign cardiac tumors using 18F-FDG PET/CT.
J Nucl Med 2012;53:856–63.
103. Shao D, Wang SX, Liang CH, Gao Q. Differentiation of malignant from benign
heart and pericardial lesions using positron emission tomography and computed
tomography. J Nucl Cardiol 2011;18:668–77.
104. Nensa F, Tezgah E, Poeppel TD, Jensen CJ, Schelhorn J, Kohler J et al.
Integrated 18F-FDG PET/MR imaging in the assessment of cardiac masses: a
pilot study. J Nucl Med 2015;56:255–60.
105. van Dijk VF, Delnoy PPHM, Smit JJJ, Misier RAR, Elvan A, van Es HW et al.
Preliminary findings on the safety of 1.5 and 3 Tesla magnetic resonance imaging
in cardiac pacemaker patients. J Cardiovasc Electrophysiol 2017;28:806–10.
974 M.S. Nazir et al.
IMAGE FOCUS doi:10.1093/ehjci/jey073
Online publish-ahead-of-print 26 May 2018
....................................................................................................................................................
Lung abscess seen on echocardiography
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A 68-year-old woman presented with
worsening shortness of breath on exer-
tion. She had a past medical history signifi-
cant for heart failure with preserved
ejection fraction and pulmonary
Mycobacterium abscessus infection. Chest
radiograph showed bilateral pleural effu-
sions with bibasilar airspace disease.
Transthoracic echocardiography (TTE)
showed a normal ejection fraction but
also revealed a hyperechoic mass in the
pleural space lateral to the left ventricle
(Panels A and B). Given these findings,
computed tomography (CT) scan of the
chest was ordered and showed a left
lower lobe consolidation with interval
areas of low attenuation concerning for
abscess formation (Panels C and D). In
addition to treatment for heart failure
exacerbation, she received antibiotic
therapy for suspected pulmonary M.
abscessus infection. Invasive interventions
were avoided given her several
comorbidities.
Mycobacterium abscessus is a rapidly
growing mycobacterium that is known to
cause pulmonary infections. In patients
with suspected infection, radiographic evi-
dence is important in making a diagnosis.
Evaluation generally involves chest radiograph and CT scan, but other imaging modalities, including TTE, may aid in detection.
Supplementary data are available at European Heart Journal - Cardiovascular Imaging online.
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